The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Satellite Symposium | Patient with R/R CLL—Latin American perspective

The virtual Lymphoma Hub Satellite Symposium, at the European School of Haematology (ESH) ‘2nd How to Diagnose and Treat: Lymphoma’ conference, saw a panel of international experts come together to discuss how to manage patients with relapsed and/or refractory (R/R) lymphoma. Professor Astrid Pavlovsky, Fundaleu, Buenos Aires, AR, discussed how she would treat a patient with chronic lymphocytic leukemia (CLL) who has relapsed after treatment with venetoclax + rituximab.

Satellite Symposium | Patient with R/R CLL— Latin American perspective

Professor Astrid Pavlovsky begins with an overview of the prevalence of common B-cell non-Hodgkin lymphoma types in Central and South America. She then highlights the lack of targeted therapies and diagnostic techniques in some Latin American countries.

Astrid Pavlovsky recommends therapeutic intervention with a Bruton’s tyrosine kinase (BTK) inhibitor, and presented data from the ELEVATE CLL R/R study, which compared ibrutinib versus acalabrutinib for the treatment of high-risk CLL.

Satellite Symposium | Patient with R/R CLL— Latin American perspective

If you would like to download the slides from Astrid Pavlovsky's presentation, click below.

Download here

Share: